Quadra Logic Technologies Inc. deal

Under the original agreement, Cyanamid received worldwide rights to the drugs to treat cancer, venereal warts and psoriasis. QLTIF was to receive 26-35 percent of sales. QLTIF said it may exercise its option to reaquire full rights to BPD.

The company said it did not expect that any changes to the pact would affect the marketing plans for Photofrin, the anticipated timing of marketing approvals in Japan and Europe, or the anticipated first-quarter 1994 NDA filing in the U.S. ...